Vitamin D: Should a regular dose be part in immunomodulation of regulatory T cells in immunomediated diseases? Gerlies Treiber, Barbara Prietl, Thomas.

Slides:



Advertisements
Similar presentations
Vitamin D Supplementation and Immune Response to Antarctic Winter S.R. Zwart, 1 S.K. Mehta, 2 R. Ploutz-Snyder, 1 Y. Bourbeau, 2 J.P. Locke, 3 D.L. Pierson,
Advertisements

Developing Immunotherapy for Autoimmune Diseases
THE EFFECTS OF INTERMITTENT VITAMIN D3 SUPPLEMENTATION ON MUSCLE STRENGHT AND METABOLIC PARAMETERS IN POSTMENOPAUSAL WOMEN WITH TYPE 2 BIABETES: A RANDOMIZED.
T-cell Immunoregulation and the Response to Immunotherapy Harold S. Nelson. MD Professor of Medicine National Jewish Health and University of Colorado.
Mobilization of Regulatory Immune Cells Utilizing GM-CSF in Experimental Myasthenia Gravis Matthew N. Meriggioli, M.D. Neuromuscular Disorders Program.
Cord Blood-Derived Regulatory T Cells: A Novel Cure for Graft-Versus-Host-Disease Siddharth Damania 2007.
Regulatory T-cells and Autoimmunity Uma Chandrasekaran Graduate Student, Medical College of Georgia Bits Embryo Lecture.
Gui-Qiang Wang Department of Infectious Diseases
Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:
The four major subsets of CD4 T cells Angelika Schmidt Defense against intracellular viruses and bacteria Autoimmunity Th1 Defense against extracellular.
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
Vitamin E and Immune Function Kate Osei-Boadi MS Human Nutrition
Six-monthly vitamin A from 1 to 6 years of age DEVTA: cluster-randomised trial in 1 million children in North India Shally AWASTHI (KG Medical Univ, Lucknow,
Correspondence: Efficacy of daily 800 IU vitamin D supplementation in reaching vitamin D sufficiency in nursing home residents:cross-sectional.
Westerweel PE et al. Eur Heart J 2008;29:
Nat. Rev. Endocrinol. doi: /nrendo
Dose-response and kinetics of vitamin D supplementation
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 2 Response after initial increase in total tumour burden
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 4 The gut microbiota directly influences T-cell differentiation
Figure 1 Induction of immune tolerance
Figure 2 Systemic immune responses to cryptococcal antigen
Figure 3 The fat–intestine–kidney axis
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.
Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.
Jagadeesh Bayry, Jean-François Gautier  Cell Metabolism 
Nat. Rev. Endocrinol. doi: /nrendo
Figure 1 Metabolic profiling as a tool for studying rheumatic diseases
Figure 2 The association between CD8+ T‑cell density of the tumour
Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Algorithm for the determination of the clinical
Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.
Nat. Rev. Rheumatol. doi: /nrrheum
Figure 3 Differentiation and functional control of T-cell subsets
The inhibition of PI3K and Akt in human T cells selectively inhibits the proliferation of human Tregs compared with Tconvs in a dose-dependent manner.
Figure 3 Multi-hit model for autoimmune diseases
Nat. Rev. Neurol. doi: /nrneurol
The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Nat. Rev. Endocrinol. doi: /nrendo
Figure 2 Logistical requirements for autologous
Nat. Rev. Endocrinol. doi: /nrendo
Supplemental Figure 1A Pt Pt Pre-treatment
Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Rheumatol. doi: /nrrheum
Docosahexaenoic Acid Alleviates Atopic Dermatitis in Mice by Generating T Regulatory Cells and M2 Macrophages  Karyn A. Haitz, Niroshana Anandasabapathy 
Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Nephrol. doi: /nrneph
Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets
Figure 3 Tumours secrete factors that cause systemic immunosuppression
Figure 1 The human adaptive immune profile in multiple sclerosis (MS)‏
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 2 Phenotypes of osteoarthritis
Figure 3 Underlying mechanisms of TREG cells in atherosclerosis
Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels in dialysis patients. Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels.
Human Treg Classes Balance Immunosuppression
Meet the Ikaros Family IL-2 Helios CD103 GITR Naïve CD4+ T cell
Figure 4 Treponema pallidum invasion
Celiac disease as a model for SLE
Kinetics of GIFT15 Breg vs B-cell treatment in mice with EAE
Anti-PD-1H Antibody Prevents Graft Versus Host Disease
DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.
Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.
Long-lived antibody-secreting cells in the bone marrow, induced by PfCelTOS vaccines containing various adjuvant formulations with emulsion doses of 0.5%
Immunological effects of anticancer therapy.
Presentation transcript:

Vitamin D: Should a regular dose be part in immunomodulation of regulatory T cells in immunomediated diseases? Gerlies Treiber, Barbara Prietl, Thomas Pieber Department for Endocrinology and Metabolism Medical University Graz 3rd Immunology Summit, Baltimore, 30. September 2014

The role of regulatory T-cells in autoimmunity Buckner, Nat Rev Immunol, 2010

Effects of Vitamin D in the immune system Bouillon, Endocrine Reviews, 2008 Treg

Vitamin D supplementation and regulatory T cells in healthy humans Pilot study1x IU Cholecalciferol n50 Age (yrs)31±8 Females (%)64 BMI (kg/m²)23.3±4.3 Prietl B, Pilz S et al IMAJ 2010

IU Vit D3 Prietl B, Treiber G et al Eur J Nutr 2014 r=0.339 p=0.009 Baseline

Significant increase in % Treg in CD4 pos T cells Unchanged Treg suppression function in healthy humans Other immune cells not effected No treatment related side effects Prietl B, Treiber G et al Eur J Nutr 2014 r=0.640 p< <0.001

Regulatory T cells in Typ 1 Diabetes T1D: no global deficiency in Treg cell numbers, but functional capacity like suppression of Treg cells is impaired. (reviewed in Bruckner Nat Immun 2010)  Targeting the Treg population directly in vivo to increase frequency and/or function of Treg Analog of active form of vitamin D (1,25(OH) 2 D 3 ) increased CD4 + CD25 + Treg in pancreatic lymph nodes in NOD mice. (Gregori 2002) VitD3 increased CD4 + CD25 + FoxP3 + T cells in pancreatic lymph nodes and reduced diabetes development in NOD mice. (Takiishi Diabetes 2014) 2000 IU VitD3 increased regulatory CD4 + CD25 + FoxP3 + T cells and slower decline of residual ß-cell function in new onset T1D. (Gabbay APDM 2012)

RCT: Vit D3 in patients with T1D 30 Patients with new-onset T1D (<12 weeks) Intervention 12 month: – oral therapy of cholecalciferol (70IU/kg bodyweight/day) – or placebo Immunologic Assessment at month 0, 3, 6 and 12: – Immune phenotyping: FACS-analysis CD4 pos CD25 hi Foxp3 pos CD127 dim Treg Th-Subtypes (Th1, Th2, Th17) DC, B-cells, NK, NKT-cells – functional tests: FACS sorted Treg and Teff ex vivo suppression co-cultures ( 3 H-thymidine incorporation) Apoptosis (AnnexinV/7-AAD)

RCT: Vit D3 in T1D Treiber G et al in preperation

No significant effect on the frequency of other peripheral immune cells – Th1 /Th2 / Th17 cells – B cells – Cells from the innate immune system RCT: Vit D3 in T1D

p=0.078 p=n.s. p=0.004

Treg origin: Thymus and Gut associated lymphoid tissue Li L et al Clin Immun 2011 GALT

GALT: interface for maintenace of immune homostasis T1D: Increased intestinal permeability precedes clinical onset of type 1 diabetes. (Bosi Diabetologia 2006) Cow milk, early cereal exposure and enterovirus infection riskfactors for islet autoimmunity. (Lempainen DMRR 2012) T1D: reduced regulatory Foxp3 + T cells in duodenal biopsies (Badami Diabetes 2011) IBD: Decreased frequency of CD4 + Foxp3 + Treg in PBMC and increased Foxp3 + cells in inflamed mucosa (Wang JDD 2011). Increased apoptosis of regulatory T lymphocytes in peripheral blood and in mucosa. (Veltkamp C Gut 2011)  Vit D3 effect on Treg in gastrointestinal mucosa in humans unknown

Follow-up Safety Vit D3 effect on Treg in gastrointestinal mucosa in humans Screening 16 healthy volunteers Screening 16 healthy volunteers BL V2/V3 V4 V5/V6 V7 Gastro Colo Gastro Colo 4 weeks blood biopsy blood biopsy blood blood blood biopsy blood biopsy Cholecalciferol 70IU/kg BW/d Loading dose

healthy humans16 Age (yrs)25±4 Females (%)44 BMI (kg/m²)23±3 Biopsy regions systematic assessment of upper and lower GI tract Gating strategy FACS analyses

regions CD4 pos (% of CD3 pos T cells) CD3 pos (% of lymphocytes) CD8 pos (% of CD3 pos T cells) regions Treg (% of CD4 pos T cells) Plos one 2013

Vit D3: on blood Treg peripheral blood

Vit D3 on GI CD4 + and CD8 +

Vit D3 on GI Treg Baseline 8 weeks Vit D3

Vit D3 and Mikrobiom before 8 wks Vit D alters upper GI community structure Reduction of Proteobacteria Increase of richness in upper GI

Summary and Conclusion Vitamin D3 – Cholecalciferol - increases peripheral regulatory T cells in healthy humans Impaired suppressive capacity in type 1 diabetes improved with Cholecalciferol supplementation along with preservation of fasting C-peptide 8 weeks of VitD3 did not alter total number of Treg in gastrointestinal mucosa in healthy humans but showed an distinct pattern in Helios + Treg compartment Vitamin D3 elevates CD8 pos cytotoxic T cell numbers, accompanied by modulation of the gut microbiome with marked reduction of Gammaproteobacteria  Potential as adjunctive immunomodulatory therapy of immunomediated diseases like T1D in combination with other future immune therapies

Acknowledgements – Barbara Prietl – Evelyne Höller – Verena Pfeifer – Christine Neuper – Silvia Leitgeb – Anja Ribitsch All our study participants Team Diabetes Clinics ADPP Network Research support – EASD and EFSD Thank you! – Martin Tauschmann – Minar Bashir – Christoph Högenauer – Patrizia Kump – Gregor Gorkiewicz – Stefan Pilz CD4 + T cell